Review for 10.1186/s12876-020-01470-1 (2020)

Reviewer’ s report
Title: Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a
pancreatic neuro-endocrine tumor: a case report.
Version: 0Date: 10 Jul 2020
Reviewer: Research Square Reviewer 1
Reviewer's report:
PEER REVIEWER ASSESSMENTS:RELEV ANCE - Does this case report make a contribution to medical knowledge, have
educational value, or highlight the need for a change in clinical practice or diagnostic/prognosticapproaches?Yes, this report contributes to medical knowledge
CASE DESCRIPTION - Are the details of the case sufficiently well described to understand the
patient's symptoms and course of treatment?Yes, the description of the case is sufficient
DIAGNOSIS/INTERPRETATION - Based on the facts presented, are the diagnosis, interpretation,
and course of treatment medically sound?Yes, the work described is medically sound
DISCUSSION OF THE CASE - Does the discussion appropriately analyse the importance of the
findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Has an adequate literature review pertinent to the case been included?Yes, the case is discussed fully in the context of the literature
OVERALL MANUSCRIPT POTENTIAL - Could an appropriately REVISED version of this
work represent a technically sound contribution?Probably - with minor revisions
PEER REVIEWER COMMENTS:GENERAL COMMENTS: This is very nice case report with a new treatment option. Is well
written and provides new knowledge
The major findings of the manuscript is a response to PPRT to control hypercalcemia. This is a
novel approach.
This paper did not have any unusual or novel methods.u
This work helped to contribute to the field by its main finding being the possibility to use PPRT as
a way of control de neuroendocrinoe tumor and its hormonal product. In this case calcitriol.
Other researchers can use the information presented in this paper in their own work by using this
type of treatment to treat similar patients.
REQUESTED REVISIONS:
I would suggest to use the term 1,25 OH Vitamin D instead of calcitriol given it is a more technicalterm. However, this case report look goog in its current form
ADDITIONAL REQUESTS/SUGGESTIONS:
None
Publons Reviewer Recognition. Springer Nature can send verification of this review directly to
Publons (a subsidiary of Clarivate Analytics). If you would like to take advantage of this service,please click on the “Yes” option below. Your name, email address, title of the reviewed
manuscript, name of the journal, and date of your review submission (the “Review Data”) will
then be transmitted to Publons upon publication of the manuscript. If you have already registeredat Publons, they will notify you of the receipt of this review and update your profile as per yoursettings and their policy. If you are not registered with Publons, you will receive an email fromthem asking you to register in order for them to be able to recognize your review on your newprofile page. Publons may use the Review Data to generate derivative metadata for the benefit ofPublons and you as a reviewer, carefully considering the sensitivity of such information. Forexample, Publons may verify your record as a reviewer by updating your profile published on itswebservice if you have registered for such service or help editors to identify candidate reviewers.Please find the details of processing in Publons’ privacy policy https://publons.com/about/terms
No
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
YesDoes the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
YesAre the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
YesAre you able to assess any statistics in the manuscript or would you recommend an
additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further
assessment in your comments to the editors.
Not relevant to this manuscriptQuality of written English
Please indicate the quality of language in the manuscript:
Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of thismanuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below.
If your reply is yes to any, please give details below.
This reviewer has been recruited by a partner organization, Research Square. Reviewers with
declared or apparent competing interests are not utilized for these reviews. This reviewer hasagreed to publication of their comments online under a Creative Commons Attribution Licenseattributed to Research Square and was paid a small honorarium for completing the review within aspecified timeframe. Honoraria for reviews such as this are paid regardless of the reviewerrecommendation.
Reviewer Publication Consent. I agree for my report to be made available under an Open Access
Creative Commons CC-BY License (http://creativecommons.org/licenses/by/4.0) if this manu-script is accepted for publication. Any comments that I do not wish to be included in the publishedreport have been included as confidential comments to the editor, which will not be published.Ifyou are not happy for us to publish this report, please contact the editorial office before completing
the review.If you wish, you can include your name in your published report. Please note you must
decide whether to include your name at the start of the process and confirm this decision whenever
prompted. If you change your decision later, we will not be able to publish your name.
I agree to the terms of the CC-BY 4.0 license; please publish my name with my report.